Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
Titel:
Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds
Auteur:
Gantz, Ira Sokolova, Liubov Jain, Lokesh Iredale, Carol O'Neill, Edward A. Wei, Ziwen Lam, Raymond Suryawanshi, Shailaja Kaufman, Keith D. Engel, Samuel S. Lai, Eseng